PRAKASH MASAND to Adult
This is a "connection" page, showing publications PRAKASH MASAND has written about Adult.
Connection Strength
0.439
-
Health care resource utilization and costs associated with switching versus augmenting antidepressant monotherapy in second-line treatment of major depressive disorder. J Affect Disord. 2025 Dec 15; 391:119787.
Score: 0.054
-
The real-world impact of cariprazine on short- and long-term disability outcomes among commercially insured patients in the United States. J Med Econ. 2025 Dec; 28(1):335-345.
Score: 0.053
-
Undifferentiated Embryonal Sarcoma of the Liver (UESL): A Single-Center Experience and Review of the Literature. J Pediatr Hematol Oncol. 2016 05; 38(4):261-8.
Score: 0.029
-
Quetiapine augmentation for depression: dosing pattern in routine practice. Int Clin Psychopharmacol. 2015 Jan; 30(1):54-8.
Score: 0.026
-
Aripiprazole augmentation for major depressive disorder: dosing patterns in a naturalistic treatment setting. Int Clin Psychopharmacol. 2014 Mar; 29(2):116-9.
Score: 0.025
-
A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. Psychosomatics. 2009 Jan-Feb; 50(1):78-86.
Score: 0.017
-
Criteria for defining symptomatic and sustained remission in bipolar I disorder: a post-hoc analysis of a 26-week aripiprazole study (study CN138-010). Psychopharmacol Bull. 2008; 41(2):12-23.
Score: 0.016
-
Prevalence of irritable bowel syndrome in obsessive-compulsive disorder. CNS Spectr. 2006 Jan; 11(1):21-5.
Score: 0.014
-
The effect of adjunctive cariprazine on symptoms of anhedonia in patients with major depressive disorder. J Affect Disord. 2025 Sep 15; 385:119366.
Score: 0.013
-
Clinical Presentation and Medium-Term Outcomes of Children With Anomalous Aortic Origin of the Left Coronary Artery: High-Risk Features Beyond Interarterial Course. Circ Cardiovasc Interv. 2023 05; 16(5):e012635.
Score: 0.012
-
Does a preexisting anxiety disorder predict response to paroxetine in irritable bowel syndrome? Psychosomatics. 2002 Nov-Dec; 43(6):451-5.
Score: 0.011
-
Dobutamine stress cardiac MRI is safe and feasible in pediatric patients with anomalous aortic origin of a coronary artery (AAOCA). Int J Cardiol. 2021 Jul 01; 334:42-48.
Score: 0.010
-
Biomarkers for liver disease in urea cycle disorders. Mol Genet Metab. 2021 06; 133(2):148-156.
Score: 0.010
-
The Rapid Mood Screener (RMS): a novel and pragmatic screener for bipolar I disorder. Curr Med Res Opin. 2021 01; 37(1):135-144.
Score: 0.010
-
The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis. J Affect Disord. 2020 11 01; 276:576-584.
Score: 0.010
-
Cariprazine for the treatment of bipolar mania with mixed features: A post hoc pooled analysis of 3 trials. J Affect Disord. 2019 10 01; 257:600-606.
Score: 0.009
-
Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: Focus on Treatment Outcomes in an Asiatic Sample. Adv Ther. 2018 10; 35(10):1656-1670.
Score: 0.008
-
Myocardial Stress Perfusion MRI: Experience in Pediatric and Young-Adult Patients Following Arterial Switch Operation Utilizing Regadenoson. Pediatr Cardiol. 2018 Aug; 39(6):1249-1257.
Score: 0.008
-
Dynamic contrast enhanced magnetic resonance lymphangiography: Categorization of imaging findings and correlation with patient management. Eur J Radiol. 2018 Apr; 101:129-135.
Score: 0.008
-
A prospective multicenter study of competency evaluations by psychiatric consultation services. Psychosomatics. 1998 Jan-Feb; 39(1):55-60.
Score: 0.008
-
Genetic Variants Within Molecular Targets of Antipsychotic Treatment: Effects on Treatment Response, Schizophrenia Risk, and Psychopathological Features. J Mol Neurosci. 2018 Jan; 64(1):62-74.
Score: 0.008
-
Genetic Variants Within Key Nodes of the Cascade of Antipsychotic Mechanisms: Effects on Antipsychotic Response and Schizophrenia Psychopathology in a Naturalistic Treatment Setting in Two Independent Korean and Italian Samples. Adv Ther. 2017 06; 34(6):1482-1497.
Score: 0.008
-
The Impact of a Single Nucleotide Polymorphism in SIGMAR1 on Depressive Symptoms in Major Depressive Disorder and Bipolar Disorder. Adv Ther. 2017 03; 34(3):713-724.
Score: 0.008
-
Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway. BMC Psychiatry. 2016 Apr 18; 16:106.
Score: 0.007
-
A 13-week, randomized double-blind, placebo-controlled, cross-over trial of ziprasidone in bipolar spectrum disorder. J Clin Psychopharmacol. 2015 Jun; 35(3):319-23.
Score: 0.007
-
The influence of AHI1 variants on the diagnosis and treatment outcome in schizophrenia. Int J Mol Sci. 2015 Jan 22; 16(2):2517-29.
Score: 0.007
-
A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. PLoS One. 2012; 7(4):e34757.
Score: 0.005
-
Psychometric properties of the Patient Health Questionnaire-15 (PHQ-15) for measuring the somatic symptoms of psychiatric outpatients. Psychosomatics. 2009 Nov-Dec; 50(6):580-5.
Score: 0.005
-
History of depressive and/or anxiety disorders as a predictor of treatment response: a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Aug 31; 33(6):996-1002.
Score: 0.004
-
Childhood abuse and treatment response in patients with irritable bowel syndrome: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. J Clin Pharm Ther. 2009 Feb; 34(1):79-88.
Score: 0.004
-
History of early abuse as a predictor of treatment response in patients with fibromyalgia: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. World J Biol Psychiatry. 2009; 10(4 Pt 2):435-41.
Score: 0.004
-
Paroxetine: safety and tolerability issues. Expert Opin Drug Saf. 2008 Nov; 7(6):783-94.
Score: 0.004
-
Polypharmacy in pregnant women with major psychiatric illness: a pilot study. J Psychiatr Pract. 2007 Nov; 13(6):385-92.
Score: 0.004
-
A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. Am J Med. 2007 May; 120(5):448-54.
Score: 0.004
-
Cerebral arteriovenous fistula to pulmonary artery onyx embolization. J Perinatol. 2007 Apr; 27(4):238-40.
Score: 0.004
-
A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol. 2006 Dec; 26(6):653-6.
Score: 0.004
-
Clinical variables associated with early administration of antipsychotics in bipolar mania. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Jan; 30(1):151-4.
Score: 0.003